Pacira BioSciences, Inc. (PCRX)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.46B
Last updated: Nov 17, 2026 at 3:04 AM ET
Pacira BioSciences, Inc. (PCRX) Statistics
Pacira BioSciences (PCRX) has a market cap of $1.46B and an enterprise value of $1.50B. Its share count is down 9.48% from a year earlier. Its return on invested capital of 4.21% compares with a 9.88% median across 10 similar companies.
Total Valuation
Enterprise value is 3.20% above the market cap, as debt exceeds cash.
| Market Cap | $1.46B |
|---|---|
| Enterprise Value | $1.50B |
| Latest price (Nov 17, 2026) | $36.48 |
Key Dates
The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 2.0x and 2.0x. Its year-end P/E ranged from 5.9x to 240.3x from 2016 to 2025.
| P/E Ratio | 20.0x |
|---|---|
| Forward P/E | 12.1x |
| P/S Ratio | 2.0x |
| Forward P/S | 2.0x |
| P/B Ratio | 2.0x |
| P/TBV Ratio | 3.5x |
| P/FCF Ratio | 8.6x |
| P/OCF Ratio | 8.2x |
| PEG Ratio | 2.3 |
Enterprise Valuation
Counting debt and cash, the company is valued at 12.2x EBITDA and 8.9x free cash flow.
| EV / Earnings | 39.8x |
|---|---|
| EV / Sales | 2.0x |
| EV / EBITDA | 12.2x |
| EV / EBIT | 35.5x |
| EV / FCF | 8.9x |
Price Statistics
The stock is up 54.45% over 52 weeks and trades 16.22% above its 50-day average.
| Beta (1Y) | 0.06 |
|---|---|
| 52-Week Change | +54.45% |
| 1-Month Change | +0.39% |
| 3-Month Change | +52.00% |
| 6-Month Change | +62.57% |
| 5-Year Change | -30.39% |
| 10-Year Change | +14.43% |
| Total Return (1Y) | +54.45% |
| Total Return (3Y CAGR) | +9.37% |
| Total Return (5Y CAGR) | -8.31% |
| Return vs SPY (1Y) | +38.01% |
| Max Drawdown (1Y) | -28.19% |
| Max Drawdown (3Y) | -67.02% |
| Sharpe Ratio (1Y) | 0.80 |
| Correlation with SPY (1Y) | 0.02 |
| 50-Day Average | $31.39 |
| 200-Day Average | $25.73 |
| 52-Week Range | $18.80 to $36.67 |
| RSI (14 Days) | 82.9 |
| Average Volume (20 Days) | 1.07M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 4.68x current liabilities, and total debt is 0.41x shareholder equity.
| Current Ratio | 4.68x |
|---|---|
| Quick Ratio | 3.65x |
| Debt / Equity | 0.41x |
| Debt / EBITDA | 2.40x |
| Debt / FCF | 1.74x |
| Interest Coverage | 3.01x |
Returns and Efficiency
Return on invested capital is 4.21% over the last 12 months, against a 5-year average of 0.68%.
| Return on Equity (ROE) | 5.30% |
|---|---|
| Return on Assets (ROA) | 3.14% |
| Return on Invested Capital (ROIC) | 4.21% |
| Return on Capital Employed (ROCE) | 3.94% |
| ROE (5Y Average) | 0.58% |
| ROA (5Y Average) | 0.15% |
| ROIC (5Y Average) | 0.68% |
| Asset Turnover | 0.59x |
| Inventory Turnover | 1.20x |
| Receivables Turnover | 5.82x |
| Cash Conversion Cycle | 327 days |
Scores
PCRX has an Altman Z-Score of 2.79, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 8 of 9, in the strong band of 8 or 9.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 2.79 |
|---|---|
| Altman Z Zone | Grey |
| Piotroski F-Score | 8 of 9 |
| Piotroski Strength | Strong |
Income Statement
Revenue of $743.30M over the last 12 months is up 3.70% from the 12 months before.
| Revenue | $743.30M |
|---|---|
| Revenue Growth (YoY) | +3.70% |
| Gross Profit | $585.19M |
| Operating Income | $35.78M |
| Pretax Income | $36.94M |
| Net Income | $37.73M |
| EBITDA | $122.58M |
| EBIT | $42.37M |
| Reported EPS (TTM) | $1.82 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 59.36% of the $1.20B in total assets.
| Cash and Equivalents | $246.96M |
|---|---|
| Total Debt | $293.59M |
| Net Debt | $46.63M |
| Net Debt Per Share | $1.17 |
| Working Capital | $464.13M |
| Shareholder Equity | $712.32M |
| Book Value Per Share | $17.87 |
| Tangible Book Value | $419.79M |
| Tangible Book Per Share | $10.53 |
| Total Assets | $1.20B |
| Total Liabilities | $490.32M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $7.90M of capital spending, operating cash flow left $169.00M of free cash flow.
| Operating Cash Flow | $176.90M |
|---|---|
| Capital Expenditures | $7.90M |
| Free Cash Flow | $169.00M |
| FCF Per Share | $4.23 |
| Depreciation and Amortization | $88.91M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 4.81%, against a 5-year average of 5.25%.
| Gross Margin | 78.73% |
|---|---|
| Operating Margin | 4.81% |
| Pretax Margin | 4.97% |
| Net Margin | 5.08% |
| EBITDA Margin | 16.49% |
| EBIT Margin | 5.70% |
| FCF Margin | 22.74% |
| Gross Margin (5Y Average) | 77.37% |
| Operating Margin (5Y Average) | 5.25% |
| Net Margin (5Y Average) | 0.62% |
Growth
Revenue fell 18.33% a year over 3 years, and EPS 2.78% a year.
| Revenue Growth (3Y CAGR) | -18.33% |
|---|---|
| Revenue Growth (5Y CAGR) | +11.07% |
| EPS Growth (3Y CAGR) | -2.78% |
| EPS Growth (5Y CAGR) | +1.59% |
| FCF Growth (3Y CAGR) | +5.86% |
| FCF Growth (5Y CAGR) | +28.35% |
| Operating Income Growth (3Y CAGR) | -31.62% |
| Book Value Per Share Growth (2Y CAGR) | -1.77% |
| Tangible Book Per Share Growth (2Y CAGR) | +28.49% |
Dividends and Yields
PCRX does not pay a dividend. Its free cash flow yield is 11.62%.
| Earnings Yield | 5.00% |
|---|---|
| FCF Yield | 11.62% |
| Buyback Yield | 6.77% |
| Shareholder Yield | 6.77% |
Peer Position
Against 11 similar companies, PCRX has the 4th highest P/E.
P/E RatioPeer median 10.7x
P/S RatioPeer median 2.0x
ROICPeer median 9.88%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +19.68%
| P/E Ratio | 20.0x vs 10.7x median |
|---|---|
| P/S Ratio | 2.0x vs 2.0x median |
| ROIC | 4.21% vs 9.88% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +3.70% vs +19.68% median |
Analyst Forecast
Consensus estimates put revenue growth at 4.23% and EPS growth at 21.44% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +4.23% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +21.44% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About PCRX
What is PCRX's market cap?
Pacira BioSciences has a market cap of $1.46B. Its enterprise value, which adds debt and subtracts cash, is $1.50B.
What is PCRX's P/E ratio?
Pacira BioSciences has a trailing P/E ratio of 20.0x and a forward P/E of 12.1x.
How many shares of PCRX are outstanding?
Pacira BioSciences has 39.86M shares outstanding. The count is down 9.48% from a year earlier.
Does PCRX pay a dividend?
No. Pacira BioSciences does not pay a dividend.
How much debt does PCRX have?
Pacira BioSciences has $293.59M of total debt and $246.96M of cash and equivalents, a net debt position of $46.63M.
PCRX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors